IL6 and type 2 diabetes mellitus: Studies involving patients with type 2 diabetes have shown that daily γ-oryzanol intake reduces systemic inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and interferon-gamma (IFN-γ), indicating its anti-inflammatory efficacy in metabolic contexts [82].